This drugmaker is developing breakthroughs like an 'EpiPen for heart attacks.' The market has yet to give it credit
The key to its growth are a non-opioid pain reliever, a potential blockbuster lupus treatment and a drug that has been dubbed an "EpiPen for heart attacks." ...
Elon Musk says we used to find medicine like random sticks in the woods — now we can program it like an app and basically 'cure almost anything'
Biotech is starting to sound less like medicine and more like software, and SpaceX and Tesla CEO Elon Musk thinks that shift ...
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
Science Daily
A forgotten drug is giving new hope to kids with a rare disease
A decades-old drug once used to treat sleeping sickness is now showing surprising promise against an ultra-rare and life-threatening genetic disorder called Bachmann-Bupp syndrome (BABS). Early ...
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation
Revolution Medicines is rated a Hold due to valuation concerns, uncertain acquisition prospects, and solo commercialization.
BioPharma Dive
Servier buys into muscular dystrophy with potentially $2.7B deal
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...
BioSpace
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier. Servier is ...